Intensity Therapeutics Inc. (NASDAQ:INTS) Shares Shorted: Short Interest Up 129.4% in October

Intensity Therapeutics Inc. (NASDAQ:INTS) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totaling 87,767 shares, an increase of 129.4% from the September 30th total of 38,253 shares. Based on an average daily volume of 28,905 shares, the short-interest ratio is presently 3.0 days. Currently, 2.9% of the shares of the stock are sold short.

Intensity Therapeutics Price Performance

INTS stock traded up $0.06 on Friday, hitting $3.40. 16,111 shares of the company’s stock traded hands, compared to its average volume of 38,249. Intensity Therapeutics has a 1-year low of $3.00 and a 1-year high of $28.75. The stock has a market cap of $11.08 million, a price-to-earnings ratio of -0.95 and a beta of 2.81. The stock has a fifty day moving average of $3.80 and a 200-day moving average of $5.31. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24). On average, analysts forecast that Intensity Therapeutics will post -2.64 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on INTS. Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Monday, October 19th. Finally, HC Wainwright upped their price objective on Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

About Intensity Therapeutics

Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.

The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.